CL2017002774A1 - Secuencias de uricasa mejorada y métodos de tratamiento - Google Patents

Secuencias de uricasa mejorada y métodos de tratamiento

Info

Publication number
CL2017002774A1
CL2017002774A1 CL2017002774A CL2017002774A CL2017002774A1 CL 2017002774 A1 CL2017002774 A1 CL 2017002774A1 CL 2017002774 A CL2017002774 A CL 2017002774A CL 2017002774 A CL2017002774 A CL 2017002774A CL 2017002774 A1 CL2017002774 A1 CL 2017002774A1
Authority
CL
Chile
Prior art keywords
treatment methods
uricase sequences
improved
improved uricase
sequences
Prior art date
Application number
CL2017002774A
Other languages
English (en)
Inventor
Manuel Baca
Andrew C Nyborg
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of CL2017002774A1 publication Critical patent/CL2017002774A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>Se describen secuencias de uricasa mejoradas que tienen efectos beneficiosos y métodos para tratar a pacientes que padecen hiperuricemia.</p>
CL2017002774A 2015-05-15 2017-11-03 Secuencias de uricasa mejorada y métodos de tratamiento CL2017002774A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562162280P 2015-05-15 2015-05-15

Publications (1)

Publication Number Publication Date
CL2017002774A1 true CL2017002774A1 (es) 2018-04-06

Family

ID=57320301

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002774A CL2017002774A1 (es) 2015-05-15 2017-11-03 Secuencias de uricasa mejorada y métodos de tratamiento

Country Status (18)

Country Link
US (3) US11098289B2 (es)
EP (1) EP3294322A4 (es)
JP (2) JP2018515101A (es)
KR (1) KR20180002828A (es)
CN (1) CN107614007B (es)
AU (2) AU2016265677B2 (es)
BR (1) BR112017024212A2 (es)
CA (1) CA2984926A1 (es)
CL (1) CL2017002774A1 (es)
CO (1) CO2017012454A2 (es)
HK (1) HK1252542A1 (es)
IL (1) IL255403A0 (es)
MX (1) MX2017014547A (es)
MY (1) MY190411A (es)
RU (1) RU2752497C2 (es)
SG (2) SG10201910522TA (es)
WO (1) WO2016187026A1 (es)
ZA (1) ZA201708507B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107614007B (zh) 2015-05-15 2022-03-25 免疫医疗有限责任公司 改进的尿酸酶序列和治疗方法
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN112410313A (zh) * 2019-08-20 2021-02-26 中国科学院上海药物研究所 一种高热稳定性尿酸酶及其应用
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
WO2021083278A1 (en) * 2019-10-29 2021-05-06 Westlake Therapeutics (Hangzhou) Co. Limited Engineering red blood cells for treating gout and hyperuricemia diseases
KR102501387B1 (ko) 2020-09-25 2023-02-24 주식회사 프로앱텍 요산산화효소-알부민 접합체, 그 제조방법 및 용도
WO2022081774A1 (en) * 2020-10-13 2022-04-21 University Of Florida Research Foundation, Incorporated Self-assembling uricase fusion peptides
EP4240423A1 (en) 2020-11-03 2023-09-13 Protalix Ltd. Modified uricase and uses thereof
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
WO2022214086A1 (zh) * 2021-04-09 2022-10-13 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途
KR20240049312A (ko) * 2021-07-08 2024-04-16 주식회사 프로앱텍 Arthrobacter globiformis 유래 요산산화효소-알부민 접합체, 그 제조방법 및 그 용도
WO2023048505A1 (ko) * 2021-09-23 2023-03-30 주식회사 프로앱텍 Apn 그룹을 포함하는 링커 및 이를 이용하여 제조된 기능성 폴리펩티드 변이체-알부민 컨쥬게이트
US20250241999A1 (en) * 2021-10-15 2025-07-31 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles
CN119752761B (zh) * 2025-03-07 2025-06-17 北京化工大学 一种高产heparosan的基因工程菌及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09154581A (ja) * 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
PL220873B1 (pl) 1998-08-06 2016-01-29 Mountain View Pharmaceuticals Roztwór chromatograficznie oczyszczonej tetramerycznej urykazy
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
IL141221A0 (en) 1998-08-06 2002-03-10 Univ Duke Urate oxidase
DK2316475T3 (da) * 1998-08-06 2017-11-20 Mountain View Pharmaceuticals Inc Isoleret tetramer urikase
ATE526401T1 (de) * 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
NZ562291A (en) * 2005-04-11 2010-02-26 Savient Pharmaceuticals Inc A variant form of urate oxidase and use thereof
HU229068B1 (hu) 2005-04-11 2013-07-29 Savient Pharmaceuticals Urát oxidáz változatok és alkalmazásuk
EP3567113A1 (en) * 2007-06-06 2019-11-13 Monsanto Technology LLC Genes and uses for plant enhancement
US20130305398A1 (en) * 2012-02-16 2013-11-14 Marie Coffin Genes and uses for plant enhacement
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
CN107614007B (zh) 2015-05-15 2022-03-25 免疫医疗有限责任公司 改进的尿酸酶序列和治疗方法

Also Published As

Publication number Publication date
RU2752497C2 (ru) 2021-07-28
US10883087B2 (en) 2021-01-05
SG10201910522TA (en) 2020-01-30
MX2017014547A (es) 2018-03-15
US20190048327A1 (en) 2019-02-14
HK1252542A1 (zh) 2019-05-31
BR112017024212A2 (pt) 2018-07-17
AU2016265677A1 (en) 2018-01-04
JP2018515101A (ja) 2018-06-14
CN107614007A (zh) 2018-01-19
CO2017012454A2 (es) 2018-04-30
AU2016265677B2 (en) 2021-12-09
US20180258406A1 (en) 2018-09-13
EP3294322A1 (en) 2018-03-21
EP3294322A4 (en) 2018-12-12
ZA201708507B (en) 2018-11-28
US11098289B2 (en) 2021-08-24
AU2022200104A1 (en) 2022-02-03
SG11201708759YA (en) 2017-11-29
WO2016187026A1 (en) 2016-11-24
CA2984926A1 (en) 2016-11-24
CN107614007B (zh) 2022-03-25
RU2017143580A3 (es) 2019-12-16
KR20180002828A (ko) 2018-01-08
MY190411A (en) 2022-04-21
RU2017143580A (ru) 2019-06-17
US20210254024A1 (en) 2021-08-19
JP2021184733A (ja) 2021-12-09
IL255403A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
CL2017002774A1 (es) Secuencias de uricasa mejorada y métodos de tratamiento
IL273824A (en) Methods of using ehmt2 inhibitors in the treatment or prevention of blood disorders
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
PT3142637T (pt) Formulações e métodos de tratamento de queratina
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
EA201791095A1 (ru) Способ лечения рака
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
IL256103B (en) Compositions and methods for treating celiac sprue disease
MX2015003701A (es) Composiciones para tratamiento.
TW201613587A (en) Medical treatments based on anamorelin
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
ZA201703467B (en) Methods of treating ocular conditions
MX394452B (es) Inhibicion de la actividad de olig2.
EP3302695C0 (en) MUSCLE TREATMENT DEVICES
EP3595688A4 (en) GENE THERAPY TO TREAT FAMILY HYPERCHOLESTEROLEMIA
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
MD3364975T2 (ro) Combinație de trazodonă și gabapentină pentru tratamentul durerii
IL249947B (en) Tissue inhibitor of metalloproteinase type 3 variants, compositions and methods
EA201790537A1 (ru) Дипептидилкетоамидные соединения и их применение для лечения и/или предотвращения накопления жира
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.